高强度聚焦超声无创治疗子宫肌瘤与子宫腺肌病的疗效与安全性回顾性队列研究
回顾性分析本院2020年3月至2023年10月接受高强度聚焦超声无创治疗的435例子宫肌瘤与78例子宫腺肌病患者,子宫肌瘤治疗成功率94.71%,子宫腺肌病96.15%,治疗后1、3、6个月临床症状改善与肌瘤缩小较治疗期更好(P<0.05),治疗期间无严重不良反应,作者认为安全且值得临床应用。
要点
- 子宫肌瘤435例HIFU治疗成功率94.71%,子宫腺肌病78例成功率96.15%。
- 治疗后1、3、6个月临床症状改善与肌瘤缩小均优于治疗期(P<0.05)。
- 治疗期间无严重不良反应,作者认为HIFU安全且值得临床应用。
核心结论
- HIFU无创治疗子宫肌瘤与子宫腺肌病可有效改善临床症状并使肌瘤体积明显缩小,同时安全性好,作者认为值得临床应用。
研究设计与样本
- 回顾性队列研究,纳入本院2020年3月至2023年10月接受HIFU无创治疗的子宫肌瘤435例与子宫腺肌病78例,观察临床症状改善与肌瘤缩小,分析治疗期间及治疗后并发症与不良反应发生率。
诊断标准与关键数值
- 子宫肌瘤435例HIFU治疗成功率为94.71%。
- 子宫腺肌病78例HIFU治疗成功率为96.15%。
- 与治疗前相比,治疗后1个月、3个月、6个月临床症状改善与肌瘤缩小较治疗期更好(P<0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To assess the advantages of High-Intensity Focused Ultrasound (HIFU) in the treatment of uterine leiomyomas and adenomyosis.
METHODS: Patients with uterine leiomyomas (435 cases) and adenomyosis (78 cases) treated in our hospital from March 2020 to October 2023 were selected to receive non-invasive treatment with HIFU. Clinical symptom improvement and fibroid shrinkage were observed, and the incidence of complications and adverse reactions during and after treatment were analyzed.
RESULTS: The success rate of HIFU treatment in 435 cases of uterine leiomyomas was as high as 94.71%. The success rate of HIFU treatment was 96.15% in 78 cases of adenomyosis. Compared with before treatment, the improvement of clinical symptoms and the reduction of leiomyomas at one month, three months and six months after treatment were relatively better than those at the treatment period (P < 0.05). There were no serious adverse reactions in the patients during the treatment.
CONCLUSION: The noninvasive application of HIFU on leiomyomas and adenomyosis effectively improves the clinical symptoms of patients, and the volume of fibroids decreases significantly. At the same time, HIFU is safe and worthy of clinical application.
引用
- Su Z, Liu S, Wang J, et al. Retrospective cohort study on the efficacy and safety of high-intensity focused ultrasound in non-invasive treatment of uterine leiomyomas and adenomyosis. Abdom Radiol (NY). 2025. PMID: 40146310. doi:10.1007/s00261-025-04908-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。